![5-[(3-chlorophenyl)amino]-Benzo[c]-2,6-naphthyridine-8-carboxylic acid structure, CAS 1009820-21-6](/structures/100000/93271_1_1009820_21_6.png)
CAS Number1009820-21-6
Synonyms5-(3-chloroanilino)benzo[c][2,6]naphthyridine-8-carboxylic acid; 5-[(3-Chlorophenyl)amino]benzo[c][2,6]naphthyridine-8-carboxylic acid; Silmitasertib; CX-4945
Molecular FormulaC19H12O2N3Cl1
Molecular Weight349.78
Density1.5±0.1 g/cm3
Boiling Point568.5±50.0 °C at 760 mmHg
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 1009820-21-6 |
| Catalog No. | 2A-9093271 |
| Chinese Name | Silmitasertib (CX-4945) |
| Synonyms | 5-(3-chloroanilino)benzo[c][2,6]naphthyridine-8-carboxylic acid; 5-[(3-Chlorophenyl)amino]benzo[c][2,6]naphthyridine-8-carboxylic acid; Silmitasertib; CX-4945 |
| Molecular Formula | C19H12O2N3Cl1 |
| Molecular Weight | 349.78 |
| Density | 1.5±0.1 g/cm3 |
| Boiling Point | 568.5±50.0 °C at 760 mmHg |
| Storage Condition | Room temperature, dry, sealed |
| Application | CX-4945 is a potent, selective and oral casein kinase 2 (CK2) inhibitor with a Ki of 0.38 nM. |
| HTC | 2933990090 |
| PubChem ID | 49650657 |
| MDL Number | MFCD13184796 |
| SMILES | O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12 |
| InChI | InChI=1S/C19H12ClN3O2/c20-12-2-1-3-13(9-12)22-18-15-6-7-21-10-16(15)14-5-4-11(19(24)25)8-17(14)23-18/h1-10H,(H,22,23)(H,24,25) |
| InChI Key | MUOKSQABCJCOPU-UHFFFAOYSA-N |
| MSDS | msds/93271_1_1009820_21_6.pdf |
| Use of | CX-4945 is a potent, selective and oral casein kinase 2 (CK2) inhibitor with a Ki of 0.38 nM. Properties Name 5-((3-Chlorophenyl)amino)benzo[c][2,6]naphthyridine-8-carboxylic acid Synonym More Synonyms Silmitasertib (CX-4945) Biological Activity Description CX-4945 is a potent, selective and oral casein kinase 2 (CK2) inhibitor with a Ki of 0.38 nM. Related Catalog Signaling Pathways >> Autophagy >> Autophagy Signaling Pathways >> Cell Cycle/DNA Damage >> Casein Kinase Signaling Pathways >> Stem Cell/Wnt >> Casein Kinase Research Areas >> Cancer CK2α:1 nM (IC50) CK2α':1 nM (IC50) References [1]. Siddiqui-Jain A, et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res. 2010 Dec 15;70(24):10288-98. [2]. Buontempo F, et al. Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB. Oncotarget. 2016 Jan 12;7(2):1323-40. [3]. Chon HJ, et al. The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies. Front Pharmacol. 2015 Mar 31;6:70. Chemical & Physical Properties Exact Mass 349.061798 PSA 75.11000 Index of Refraction 1.789 InChIKey MUOKSQABCJCOPU-UHFFFAOYSA-N Safety Information Hazard Codes Xi HS Code 2933990090 |
| Tax Rebate | 13.0% |
| Supervision | None. MFN tariff: 6.5%. Ordinary tariff: 20.0% |
| Transport Info | Product name: Summary 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS